MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma

Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.

Study Overview

• Status: Terminated
• Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Intraocular Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Small Intestine Lymphoma; Testicular Lymphoma; B-cell Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Adult Grade III Lymphomatoid Granulomatosis
• Intervention / Treatment: Other: laboratory biomarker analysis; Biological: ipilimumab

Detailed Description

PRIMARY OBJECTIVES:

I. To characterize the safety profile of MDX-010 (ipilimumab) monoclonal antibody and identify a tolerable immunologically active dose level in B cell lymphoma patients.

II. To evaluate the clinical response rate in B cell lymphoma patients treated with MDX-010.

SECONDARY OBJECTIVES:

I. To evaluate the phenotype and function of memory T cells before and after treatment with MDX-010 by:

• Quantitation and phenotypic characterization of peripheral blood and tumor infiltrating T-cells, including cluster of differentiation (CD)4+CD25+ regulatory T cells.
• Measurement of tumor-specific T cells in peripheral blood lymphocytes.
• Measuring proliferation of memory T cells in response to recall antigens (tetanus toxoid and keyhole limpet hemocyanin [KLH]).

II. Measurement of anti-tumor antibodies in serum pre- and post-therapy. III. To evaluate the time to progression. IV. To evaluate the duration of response to treatment with MDX-010.

OUTLINE: This is a multicenter, open-label, phase I, dose-escalation study followed by a phase II study. Patients are grouped according to prior treatment with a vaccine therapy for lymphoma (yes vs no).

PHASE I: Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

PHASE II: Patients receive MDX-010 as in phase I at the MTD.

Patients are followed at 1 and 4 months and then every 6 months for up to 2 years.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologic proof of recurring or residual follicular B-cell non-Hodgkin's lymphoma (grade I or II), by Revised European American Lymphoma Classification (REAL) or World Health Organization (WHO) classifications which has relapsed or persisted after 3 or fewer conventional therapies, including chemotherapy or monoclonal antibody therapy; note: all patients with previously treated B-cell lymphomas of any histology with the exception of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) are eligible
• Tumor measurable by computed tomography (CT) scans (at least one pathologic node measuring 2.0 x 2.0 cm, or 2 nodes measuring > 1.5 x 1.5 cm after collection of tumor for immunologic analyses)
• At least one prior treatment regimen but no more than 3 prior chemotherapy regimens; patients previously treated with monoclonal antibodies or radiotherapy to a single site will be eligible; these therapies will be considered prior treatment regimens but will not be considered as prior chemotherapy; tumor vaccines will not be counted as prior therapies, as all such agents are investigational
• Absolute neutrophil count (ANC) >= 1000/uL
• Platelets (PLT) >= 75,000/uL
• Total bilirubin =< 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) =< 3 x upper limit or normal (ULN)
• Creatinine =< 1.5 x ULN
• Hemoglobin >= 8 g/dL
• Ability to provide informed consent
• Willingness to return to the Mayo Clinic Rochester or the University of California, Los Angeles for follow up
• Life expectancy >= 24 weeks
• Willingness to provide all biologic specimens as required by the protocol

Exclusion Criteria:

• Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, 3, or 4
• Any uncontrolled infection, hepatitis C virus (HCV)+ (unless HCV ribonucleic acid [RNA]-negative by polymerase chain reaction [PCR]) or hepatitis B surface antigen (HBsAg)+, or human immunodeficiency virus (HIV) positive patients or patients with known immune deficiency states
• Previous MDX-010 therapy regardless of interval since last treatment
• Prior treatment with fludarabine or 2-chlorodeoxyadenosine =< 12 months prior to registration
• Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
• New York Heart Association classification III or IV or a history of angina pectoris requiring active treatment
• Clinical evidence of central nervous system involvement by lymphoma

• Any of the following:

  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence, etc.)
• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
• Diagnosis of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL)
• Any requirement for concurrent steroid therapy, including use of inhaled steroids for asthma
• History of autoimmune disease requiring systemic therapy with immunosuppressive drugs, including but not limited to rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, or psoriasis
• Antinuclear antibody (ANA) titer or rheumatoid factor titer > 3x institutional ULN

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Treatment (ipilimumab); PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PHASE II: Patients receive MDX-010 as in phase I at the MTD.

Other: laboratory biomarker analysis; Correlative studies; Biological: ipilimumab; Given IV; Other Names: MDX-010; anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody; MDX-CTLA-4; monoclonal antibody CTLA-4

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Overall Confirmed Responses(Complete Response or Partial Response)	Confirmed response is at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease.	From registration to month 7

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Progression (Phase 2)	The time to progression is defined as the time from registration to the time of progression. Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred. The distribution of time to progression will be estimated using the method of Kaplan-Meier.	From registration to progression (up to 2 years)
Overall Survival (Phase 2)	The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.	From registration to death (up to 2 years)
Duration of Response (Phase 2)	Duration of response will be calculated from the documentation of confirmed response until the date of progression in the subset of patients who respond.	From response to progression (up to 2 years)
Mean Change in % of CD3+CD4+ for Marker HLA-DR+	Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy	Before treatment to 1 month after therapy initiation
Mean Change in % of CD3+CD4- for Marker HLA-DR+	Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy	Before treatment to 1 month after therapy initiation
Mean Change in % of CD3+CD4+ for Marker CD45RO+	Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy	Before treatment to 1 month after therapy initiation
Mean Change in % of CD3+CD4- for the Marker CD45RO+	Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy	Before treatment to 1 month after therapy initiation

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Stephen Ansell, Mayo Clinic

Study record dates

Study Major Dates

• Study Start: June 1, 2004
• Primary Completion (ACTUAL): July 1, 2008
• Study Completion (ACTUAL): October 1, 2009

Study Registration Dates

• First Submitted: August 4, 2004
• First Submitted That Met QC Criteria: August 4, 2004
• First Posted (ESTIMATE): August 5, 2004

Study Record Updates

• Last Update Posted (ESTIMATE): May 30, 2014
• Last Update Submitted That Met QC Criteria: May 22, 2014
• Last Verified: December 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Virus Diseases; Infections; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Neoplasms by Site; Disease Attributes; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; DNA Virus Infections; Tumor Virus Infections; Neoplasms, Plasma Cell; Precancerous Conditions; Leukemia, Lymphoid; Epstein-Barr Virus Infections; Herpesviridae Infections; Leukemia, B-Cell; Eye Neoplasms; Lymphoma, T-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia; Hodgkin Disease; Recurrence; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphomatoid Granulomatosis; Lymphoma, Extranodal NK-T-Cell; Intraocular Lymphoma; Leukemia, Hairy Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Immunologic Factors; Immune Checkpoint Inhibitors; Antibodies; Immunoglobulins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Ipilimumab
• Other Study ID Numbers: NCI-2012-02784 (REGISTRY: CTRP (Clinical Trial Reporting Program)); P30CA015083 (U.S. NIH Grant/Contract); U01CA069912 (U.S. NIH Grant/Contract); MC0312 (OTHER: Mayo Clinic); 6359 (CTEP)